Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

NCT02420938 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Rituximab
DRUG: Urelumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]